The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Kristine Yaffe, Michael Tocco, Ronald Carl Petersen, Catherine Sigler, Leah C. Burns, Christel Cornelius, Ara S. Khachaturian, Michael C. Irizarry, Maria C. Carrillo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

Original languageEnglish (US)
Pages (from-to)237-242
Number of pages6
JournalAlzheimer's and Dementia
Volume8
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Drug Design
Alzheimer Disease
Epidemiology
Clinical Trials
Epidemiologic Studies
Therapeutic Human Experimentation
Vulnerable Populations
Pharmaceutical Preparations
Observational Studies
Cardiovascular Diseases
Public Health
Technology
Research
Population
Therapeutics

Keywords

  • Aging
  • Alzheimer's disease
  • Dementia
  • Epidemiology
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

The epidemiology of Alzheimer's disease : Laying the foundation for drug design, conduct, and analysis of clinical trials. / Yaffe, Kristine; Tocco, Michael; Petersen, Ronald Carl; Sigler, Catherine; Burns, Leah C.; Cornelius, Christel; Khachaturian, Ara S.; Irizarry, Michael C.; Carrillo, Maria C.

In: Alzheimer's and Dementia, Vol. 8, No. 3, 05.2012, p. 237-242.

Research output: Contribution to journalArticle

Yaffe, K, Tocco, M, Petersen, RC, Sigler, C, Burns, LC, Cornelius, C, Khachaturian, AS, Irizarry, MC & Carrillo, MC 2012, 'The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials', Alzheimer's and Dementia, vol. 8, no. 3, pp. 237-242. https://doi.org/10.1016/j.jalz.2011.12.005
Yaffe, Kristine ; Tocco, Michael ; Petersen, Ronald Carl ; Sigler, Catherine ; Burns, Leah C. ; Cornelius, Christel ; Khachaturian, Ara S. ; Irizarry, Michael C. ; Carrillo, Maria C. / The epidemiology of Alzheimer's disease : Laying the foundation for drug design, conduct, and analysis of clinical trials. In: Alzheimer's and Dementia. 2012 ; Vol. 8, No. 3. pp. 237-242.
@article{7046208098f64f9fa60e9add92f1195d,
title = "The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials",
abstract = "Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.",
keywords = "Aging, Alzheimer's disease, Dementia, Epidemiology, Mild cognitive impairment",
author = "Kristine Yaffe and Michael Tocco and Petersen, {Ronald Carl} and Catherine Sigler and Burns, {Leah C.} and Christel Cornelius and Khachaturian, {Ara S.} and Irizarry, {Michael C.} and Carrillo, {Maria C.}",
year = "2012",
month = "5",
doi = "10.1016/j.jalz.2011.12.005",
language = "English (US)",
volume = "8",
pages = "237--242",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The epidemiology of Alzheimer's disease

T2 - Laying the foundation for drug design, conduct, and analysis of clinical trials

AU - Yaffe, Kristine

AU - Tocco, Michael

AU - Petersen, Ronald Carl

AU - Sigler, Catherine

AU - Burns, Leah C.

AU - Cornelius, Christel

AU - Khachaturian, Ara S.

AU - Irizarry, Michael C.

AU - Carrillo, Maria C.

PY - 2012/5

Y1 - 2012/5

N2 - Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

AB - Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

KW - Aging

KW - Alzheimer's disease

KW - Dementia

KW - Epidemiology

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84860447272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860447272&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.12.005

DO - 10.1016/j.jalz.2011.12.005

M3 - Article

C2 - 22546356

AN - SCOPUS:84860447272

VL - 8

SP - 237

EP - 242

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -